Suven Life Sciences Ltd has secured one product patent each from Eurasia, Japan and one from Mexico for its New Chemical Entities (NCEs).
A patent is a grant made by a government that confers upon the creator of an invention the sole right to make, use, and sell that invention for a set period of time.
Drugs Banned in India
Several drugs are either banned or withdrawn after introduction in the market.
Advertisement
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents.
"They are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention Deficient Hyperactivity Disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia" Suven said in a release on Tuesday.
With these new patents, Suven has 13 patents from Eurasia, 12 from Japan and 17 from Mexico. The patents may be out-licensed at phase 1 or phase 2 of clinical development, as they are the exclusive products of Suven. These patents are valid till 2029.
Source: Medindia
With these new patents, Suven has 13 patents from Eurasia, 12 from Japan and 17 from Mexico. The patents may be out-licensed at phase 1 or phase 2 of clinical development, as they are the exclusive products of Suven. These patents are valid till 2029.
Source: Medindia
Chemotherapy Drugs
Chemotherapy drugs perform like 'magic bullets' to destroy cancer cells in the body.
Advertisement
Advertisement
|
Advertisement
Latest Drug News
India's First Urinary Incontinence Drug Fesobig may offer Affordable treatment for Overactive Bladder (OAB), a widely prevalent problem among Indian men and women.
Oral anticoagulant drugs, particularly Rivaroxaban presented superior efficacy and safety than warfarin in atrial fibrillation patients with chronic kidney disease.
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.
Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.